Targeted therapy for Kaposi's sarcoma and Kaposi's sarcoma-associated herpesvirus

Current Opinion in Oncology

Volumn 19, Issue 5, 2007, Pages 452-457

  Dittmer, Dirk P ^a   Krown, Susan E ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Akt mammalian target of rapamycin; Angiogenesis; Kaposi's sarcoma; Kaposi's sarcoma herpesvirus; Viral cyclin

Indexed keywords

4 DEDIMETHYLAMINOSANCYCLINE; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; BEVACIZUMAB; BORTEZOMIB; CYCLINE; CYCLOSPORIN; DOXORUBICIN; HDM2 ANTAGONIST; IM 862; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDINAVIR; NELFINAVIR; NUTLIN 3; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; PROTEIN P53; PROTEINASE INHIBITOR; RAPAMYCIN; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT INTERLEUKIN 12; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSCOVITINE; SORAFENIB; SUNITINIB; TETRACYCLINE; UNCLASSIFIED DRUG;

AFRICA; ARTHRALGIA; CANCER GROWTH; CLINICAL TRIAL; COMPREHENSION; DEPRESSION; DEVELOPED COUNTRY; DISEASE COURSE; DRUG DOSE INCREASE; DRUG MECHANISM; FLU LIKE SYNDROME; HEMOLYTIC ANEMIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOST; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; KAPOSI SARCOMA; MAMMAL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DRUG DELIVERY SYSTEMS; HERPESVIRUS 8, HUMAN; HUMANS; SARCOMA, KAPOSI;

EID: 34548436128     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3281eb8ea7     Document Type: Review

References (50)

1. Hong YK, Foreman K, Shin JW, et al. Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma-associated herpesvirus. Nat Genet 2004; 36:683-685.
2. Wang HW, Trotter MW, Lagos D, et al. Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. Nat Genet 2004; 36:687-693.
3. Engels EA, Pfeiffer RM, Goedert JJ, et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 2006; 20:1645-1654. • A comparison of risks for cancer in the pre and post-HAART eras in the US using AIDS and cancer registries, demonstrating a declining risk for Kaposi's sarcoma and non-Hodgkin's lymphoma, but an increased risk for Hodgkin's disease.
4. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006; 118:3030-3044. • An interesting statistical analysis of the worldwide burden of cancers attributable to infectious agents, which estimates that 17.8% (1.9 million cases) of the worldwide incidence of cancer in 2002 can be attributed to infection.
5. Whitby D, Marshall VA, Bagni RK, et al. Reactivation of Kaposi's sarcoma-associated herpesvirus by natural products from Kaposi's sarcoma endemic regions. Int J Cancer 2007; 120:321-328. • An unorthodox approach that attempts to explain the high prevalence (above 90%) of KSHV in hyperendemic regions by identifying natural products present in the environment that can increase viral reactivation.
6. Sodhi A, Chaisuparat R, Hu J, et al. The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor. Cancer Cell 2006; 10:133-143. • A very thorough study showing that the KSHV vGPCR protein can activate the mTOR pathway and that mTOR may be required for KSHV-associated tumorigenesis.
7. •] showing the KSHV K1 protein can activate the Akt/mTOR pathway and that this contributes to Kaposi's sarcoma tumorigenesis.
8. Pantanowitz L, Dezube BJ, Hernandez-Barrantes S, et al. Matrix metalloproteinases in the progression and regression of Kaposi's sarcoma. J Cutan Pathol 2006; 33:793-798. • An immunohistochemical study showing that Kaposi's sarcoma lesional cells express MMPs, and that there is continued overexpression in partially regressed lesional tumor cells and infiltrating macrophages after treatment.
9. Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005; 352:1317-1323.
10. Sin SH, Roy D, Wang L, et al. Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling. Blood 2007; 109:2165-2173. • Laboratory and animal study which shows that the mTOR pathway is essential for KSHV-associated PEL and that a mechanism of PEL inhibition by the mTOR inhibitor rapamycin is to inhibit autocrine growth factors such as interleukin-6 and -10.
11. Katano H, Sato Y, Sata T. Expression of p53 and human herpesvirus-8 (HHV-8)-encoded latency-associated nuclear antigen with inhibition of apoptosis in HHV-8-associated malignancies. Cancer 2001; 92:3076-3084.
12. Krown SE, Northfelt DW, Osoba J, Stewart JS. Use of liposomal anthracyclines in Kaposi's sarcoma. Semin Oncol 2004; 31 (Suppl 13):36-52.
13. Petre CE, Sin SH, Dittmer DP. Functional p53 signaling in Kaposi's sarcoma-associated herpesvirus lymphomas: implications for therapy. J Virol 2007; 81:1912-1922. • A report which demonstrates that Nutlin-3, a p53 activator, is efficacious in PEL cell lines.
14. Martins CP, Brown-Swigart L, Evan GI. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 2006; 127:1323-1334.
15. Ventura A, Kirsch DG, McLaughlin ME, et al. Restoration of p53 function leads to tumour regression in vivo. Nature 2007; 445:661-665.
16. Xue W, Zender L, Miething C, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007; 445:656-660. •• Three reports (including [14,15]) that show that restoration and activation of wild-type p53 in established murine cancers leads to tumor regression. Provides the rationale for exploring the therapeutic potential of p53-activating agents such as Nutlin-3.
17. Swanton C, Mann DJ, Fleckenstein B, et al. Herpes viral cyclin/Cdk6 complexes evade inhibition by CDK inhibitor proteins. Nature 1997; 390:184-187.
18. Sanchez V, Spector DH. Cyclin-dependent kinase activity is required for efficient expression and posttranslational modification of human cytomegalovirus proteins and for production of extracellular particles. J Virol 2006; 80:5886-5896.
19. Taylor SL, Kinchington PR, Brooks A, Moffat JF. Roscovitine, a cyclin-dependent kinase inhibitor, prevents replication of varicella-zoster virus. J Virol 2004; 78:2853-2862.
20. Schang LM, Bantly A, Knockaert M, et al. Pharmacological cyclin-dependent kinase inhibitors inhibit replication of wild-type and drug-resistant strains of herpes simplex virus and human immunodeficiency virus type 1 by targeting cellular, not viral, proteins. J Virol 2002; 76:7874-7882.
21. Bresnahan WA, Boldogh I, Chi P, et al. Inhibition of cellular Cdk2 activity blocks human cytomegalovirus replication. Virology 1997; 231:239-247.
22. Laman H, Coverley D, Krude T, et al. Viral cyclin-cyclin-dependent kinase 6 complexes initiate nuclear DNA replication. Mol Cell Biol 2001; 21:624-635.
23. Cannon M, Cesarman E, Boshoff C. KSHV G protein-coupled receptor inhibits lytic gene transcription in primary-effusion lymphoma cells via p21-mediated inhibition of Cdk2. Blood 2006; 107:277-284. • A report that further underscores the multiple roles that the KSHV vGPCR plays in KSHV pathogenesis.
24. Upton JW, Speck SH. Evidence for CDK-dependent and CDK-independent functions of the murine gammaherpesvirus 68 v-cyclin. J Virol 2006; 80:11946-11959. • Provides experimental evidence that viral cyclins have functions that are not dependent on associated kinase activity.
25. Sadagopan S, Sharma-Walia N, Veettil MV, et al. Kaposi's sarcoma-associated herpes virus (KSHV/HHV-8) induces a sustained NF-κB activation during de novo infection of primary human dermal microvascular endothelial cells that is essential for viral gene expression. J Virol 2007; [Epub ahead of print].
26. Krug LT, Moser JM, Dickerson SM, Speck SH. Inhibition of NF-kappaB activation in vivo impairs establishment of gammaherpesvirus latency. PLoS Pathog 2007; 3:e11. • An in-vivo demonstration that underscores the importance of NF-kappa B in KSHV/γ herpesvirus pathogenesis.
27. An J, Sun Y, Fisher M, Rettig MB. Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas. Leukemia 2004; 18:1699-1704.
28. Keller SA, Schattner EJ, Cesarman E. Inhibition of NF-kappaB induces apoptosis of KSHV-infected primary effusion lymphoma cells. Blood 2000; 96:2537-2542.
29. Matta H, Chaudhary PM. The proteasome inhibitor bortezomib (PS-341) inhibits growth and induces apoptosis in primary effusion lymphoma cells. Cancer Biol Ther 2005; 4:77-82.
30. Noy A, Scadden DT, Lee JY, et al. Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team. J Clin Oncol 2005; 23:990-998.
31. Koon HB, Bubley GJ, Pantanowitz L, et al. Imatinib-induced regression of AIDS-related Kaposi's sarcoma. J Clin Oncol 2005; 23:982-989.
32. Wendel H-G, De Stanchina E, Cepero E, et al. Loss of p53 impedes the antileukemic response to BCR-ABL inhibition. Proc Natl Acad Sci U S A 2006; 103:7444-7449.
33. Dezube BJ, Krown SE, Lee JY, et al. Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: A phase II AIDS Malignancy Consortium Study. J Clin Oncol 2006; 24:1389-1394. • A randomized phase II trial of the matrix metalloproteinase inhibitor, COL-3, demonstrating activity of this agent in AIDS-associated Kaposi's sarcoma, with superior activity and better tolerance at the lower of two doses.
34. Little RF, Pluda JM, Wyvill KM, et al. Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma. Blood 2006; 107:4650-4657. • An escalating dose phase I/II clinical trial of interleukin-12, demonstrating substantial antitumor activity in patients with AIDS-associated Kaposi's sarcoma.
35. Krown SE, Lee JY, Lin L, et al. A phase I trial of protease inhibitor-based antiretroviral therapy with recombinant interferon alfa-2b in patients with HIV-related Kaposi's sarcoma. J Aquired Immun Defic Syndr 2006; 41:149-153. • A phase I trial of the combination of recombinant IFN-α with protease inhibitor-based antiretroviral therapy that established the maximum tolerated dose of IFN as part of this combination, but showed no effect on clearance of KSHV.
36. Lebbe C, Euvrard S, Barrou B, et al. Sirolimus conversion for patients with posttransplant Kaposi's sarcoma. Am J Transplant 2006; 6:2164-2168. • A retrospective study of 14 cases of posttransplant Kaposi's sarcoma, showing two complete responses, eight partial responses and five nonresponses after switching from a calcineurin inhibitor to sirolimus. Three partial responders relapsed after 5-9 months while still on sirolimus therapy. The authors stress the need for prospective studies with pharmacodynamic evaluation to better assess the mechanisms of primary and acquired drug resistance.
37. Kauffman HM, Cherikh WS, McBride MA, et al. Posttransplant de novo malignancies in renal transplant recipients: the past and present. Transpl Int 2006; 19:607-620. • A review of posttransplant malignancies from transplant registries and transplant center reports, documenting the incidence of cancers in different eras according to the type of posttransplant immunosuppression.
38. Campistol JM, Eris J, Oberbauer R, et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006; 17:581-589. • Report of a trial in renal allograft recipients randomized to either continue on cyclosporine with sirolimus and corticosteroids or to have cyclosporine withdrawn and sirolimus levels increased. Risks of skin and nonskin cancers were decreased in the group in which cyclosporine was discontinued.
39. O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006; 66:1500-1508. •• An interesting study with potentially important clinical implications that explores the mechanisms of resistance of tumor cells to mTOR inhibitors. The authors demonstrate that feedback downregulation of receptor tyrosine kinase signaling is a frequent event in tumor cells with constitutive mTOR activation. Reversal of this feedback loop by rapamycin may attenuate its therapeutic effects, whereas combination therapy that ablates mTOR function and prevents Akt activation may result in improved antitumor activity.
40. Sodhi A, Montaner S, Patel V, et al. Akt plays a central role in sarcomagenesis induced by Kaposi's sarcoma herpesvirus-encoded G protein-coupled receptor. Proc Natl Acad Sci U S A 2004; 101:4821-4826.
41. Esposito V, Palescandolo E, Spugnini EP, et al. Evaluation of antitumoral properties of the protease inhibitor indinavir in a murine model of hepatocarcinoma. Clin Cancer Res 2006; 12:2634-2639.
42. Jiang W, Mikochik PJ, Ra JH, et al. HIV protease inhibitor nelfinavir inhibits growth of human melanoma cells by induction of cell cycle arrest. Cancer Res 2007; 67:1221-1227.
43. Srirangam A, Mitra R, Wang M, et al. Effects of HIV protease inhibitor ritonavir on Akt-regulated cell proliferation in breast cancer. Clin Cancer Res 2006; 12:1883-1896. • Three reports (including [41,42]) that explore the mechanisms by which HIV protease inhibitors can inhibit cancer cell growth and which are independent of their effects on the viral protease target.
44. Martinez V, Caumes E, Gambotti L, et al. Remission from Kaposi's sarcoma on HAART is associated with suppression of HIV replication and is independent of protease inhibitor therapy. Br J Cancer 2006; 94:1000-1006. •• A retrospective analysis of 138 HIV-infected patients with Kaposi's sarcoma, including 73 who were antiretroviral naive at Kaposi's sarcoma diagnosis whose tumor response to HAART therapy was analyzed according to whether they did or did not receive protease inhibitors. Kaposi's sarcoma response was associated with suppression of HIV viremia, but not with the type of HAART regimen.
45. Sgadari C, Monini P, Barillari G, Ensoli B. Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth. Lancet Oncol 2003; 4:537-547.
46. Orem J, Otieno MW, Banura C, et al. Capacity building for the clinical investigation of AIDS malignancy in East Africa. Cancer Detect Prev 2005; 29:133-145.
47. Niedermeier A, Talanin N, Chung EJ, et al. Histone deacetylase inhibitors induce apoptosis with minimal viral reactivation in cells infected with Kaposi's sarcoma-associated herpesvirus. J Invest Dermatol 2006; 126:2516-2524. • A laboratory study in KSHV-infected primary effusion lymphoma cells demonstrating that four histone deacetylase inhibitors (depsipeptide, suberoylanilide hydroxamic acid, MS-275 and trichostatin A) induced histone hyperacetylation in all cells, KSHV reactivation in a minority of cells and apoptotic cell death in a majority of cells latently infected with KSHV.
48. Melillo B, Sausville EA, Cloud K, et al. Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes. Cancer Res 1999; 59:5433-5437.
49. Pumfery A, De la Fuente C, Berro R, et al. Potential use of pharmacological cyclin-dependent kinase inhibitors as anti-HIV therapeutics. Curr Pharm Des 2006; 12:1949-1961.
50. Toschi E, Bacigalupo I, Strippoli R, et al. HIV-1 Tat regulates endothelial cell cycle progression via activation of the Ras/ERK MAPK signaling pathway. Mol Biol Cell 2006; 17:1985-1994. • A study further elucidating the role of the HIV Tat protein in the development of Kaposi's sarcoma lesions and demonstrating that Tat can activate the Ras-extracellular signal-regulated kinase cascade.